Clinical trials: Antipsychotic
Anorexia Nervosa
A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
The aim of this pilot study is to determine the safety and efficacy of risperidone for the treatment of anorexia nervosa. Hypothesis 1: Subjects on risperidone will show a more significant decrease in body image distortion and…
- Trial name
- NCT00140426
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
The purpose of this study is to evaluate whether ITI-007 is effective in reducing symptoms associated with schizophrenia in patients who are having an acute worsening of their psychosis.
- Trial name
- NCT01499563
- Testing
- ITI-007, Risperidone
- Where
- 8 sites in United States
- Volunteers
- 335 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizoaffective Disorder
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
This study involves people who have schizophrenia or schizoaffective disorder who are currently taking antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00595504
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia With Impulsivity
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
The purpose of this study is to evaluate the effect of brexpiprazole, via functional magnetic resonance imaging (fMRI), on the right ventrolateral prefrontal cortex (VLPFC) activated by impulsive behavior.
- Trial name
- NCT02194933
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia / Schizoaffective Disorder
The Effect of Structured Medical Nutrition Therapy on Systemic Inflammation Index in Patients With Schizophrenia Receiving Antipsychotic Therapy
Patients with schizophrenia receiving long-term antipsychotic therapy are at increased risk of chronic low-grade inflammation and metabolic disturbances, which contribute to poor physical health outcomes and increased…
- Trial name
- NCT07696000
- Testing
- Modification Diet, Hospitalized Diet
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- DINA KEUMALA SARI
Schizophrenia
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
A clinical study to determine whether an investigational medication (SEP363856) changes how long it takes for food to move through the stomach into the small intestine in patients with schizophrenia.
- Trial name
- NCT05402111
- Testing
- SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
PTSD, Post-Traumatic Stress Disorder
Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years
The primary objective is to examine the percentage of patients with PTSD who were prescribed an antipsychotic over the past seven years in the VA Network 7 (AL, GA, SC) and compare the percentage on an annual basis.
- Trial name
- NCT00230893
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Tuscaloosa Research & Education Advancement Corporation
Schizophrenia, Schizoaffective Disorder
Shared Decision Making for Antipsychotic Medications
This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05416658
- Testing
- The Antipsychotic Medication Decision Aid (APM-DA)
- Volunteers
- 120 people
- Sponsor
- New York State Psychiatric Institute
Tardive Dyskinesia
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one…
- Trial name
- RE-Kinect (NCT03062033)
- Where
- 34 sites in United States
- Volunteers
- 70 people
- Sponsor
- Neurocrine Biosciences
Agitation,Psychomotor
Outcomes of Antipsychotic Medication Used in the Emergency Department
To review records of patients treated with antipsychotics (including Adasuve, Geodon, Haldol) in order to evaluate outcomes.
- Trial name
- OAMED (NCT02504450)
- Testing
- Adasuve, Alternative medications
- Volunteers
- 93 people
- Sponsor
- Wake Forest University Health Sciences
Schizophrenia, Schizoaffective
Evaluation of QTc Interval by Continuous Holter ECG Recording in Antipsychotic Drug-treated Patients With Schizophrenia
The aim of this study is to evaluate the utility of continuous Holter ECG recording with automated, computerized data analysis for measuring antipsychotic-related QTc prolongation during a 24-h period under clinical conditions
- Conditions
- Schizophrenia, Schizoaffective, Bipolar Disorder
- Trial name
- NCT00178958
- Testing
- Holter Monitor
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Social Anxiety Disorder
Geodon for the Treatment of Refractory Social Anxiety Disorder
The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment…
- Trial name
- SAD (NCT00215150)
- Testing
- Ziprasidone, Sertraline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Duke University
Delirium, Impaired Cognition
The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study
The long-term objective of the MIND-USA (Modifying the Impact of ICU-Induced Neurological Dysfunction-USA) Study is to define the role of antipsychotics in the management of delirium in vulnerable critically ill patients.
- Conditions
- Delirium, Impaired Cognition, Long Term Psychologic Disorders
- Trial name
- MIND-USA (NCT01211522)
- Testing
- Haloperidol, Ziprasidone
- Where
- 16 sites in United States
- Volunteers
- 566 people
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia, Metabolic Syndrome
Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
The study is performed in 20 different hospitals from 19 cities in China. Three sub-projects are included. About sub-project 1, we build a clinical database system and a biological sample bank for data and samples management…
- Trial name
- NCT03451734
- Testing
- antipsychotic medications, adjunctive group, metformin and lifestyle intervention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Central South University
Schizophrenia, Negative Symptoms in Schizophrenia
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
This study is a prospective, multicenter, controlled, real world study. Patients will be randomly enrolled into the test group and the control group at a ratio of 1:1 during the screening period.
- Trial name
- NCT05646264
- Testing
- Agomelatine
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Mental Health Center
Neurodevelopmental Disorders, Irritability
AP Metabolism Transcriptomics
It is known from the literature that treatment with antipsychotic drugs (AP) induces, even before changes in blood chemistry parameters, changes in gene transcription that are evident at the level of peripheral blood mononuclear…
- Trial name
- NCT06814314
- Testing
- Transcriptomic investigation
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Eugenio Medea
Psychotic Disorders, Metabolic Syndrome x
Is Health Coaching Effective for Improving Metabolic Health in People With Psychosis Disorders?
Antipsychotic medications frequently cause metabolic side-effects, such as abdominal obesity, high blood pressure, cholesterol abnormalities, and blood sugar dysregulation, all of which can lead to what is known as the Metabolic…
- Trial name
- NCT01752465
- Testing
- Health Coaching, Standard care
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Psychotic Disorders, Schizophrenia
Antipsychotics and Risk of Hyperglycemic Emergencies
The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency.
- Conditions
- Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT02582736
- Testing
- Olanzapine, Risperidone, atypical antipsychotics (other)
- Where
- Canada
- Volunteers
- 725,489 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Schizophrenia, Schizoaffective Disorder
24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
Ziprasidone is recommended to be dosed twice daily for the treatment of schizophrenia, based on peripheral pharmacokinetics and a knowledge of its half life in plasma level (5-10 hours).
- Trial name
- NCT00818298
- Testing
- ziprazidone
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Schizophrenia, Obesity & Overweight
Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side Effects
The primary objective of the study is to assess the efficacy and tolerability of a 90-day daily supplementation with a Nitraria retusa dried crushed leaves infusion on the iatrogenic metabolic side effects induced in patients…
- Conditions
- Treatment Resistant Schizophrenia, Obesity & Overweight, Abdominal Obesity
- Trial name
- NCT07817069
- Testing
- The Nitraria retusa arm
- Where
- Tunisia
- Volunteers
- 30 people
- Sponsor
- Faculty of Medicine, Sousse